JP2023553835A - 大環状化合物およびそれらの使用 - Google Patents

大環状化合物およびそれらの使用 Download PDF

Info

Publication number
JP2023553835A
JP2023553835A JP2023532465A JP2023532465A JP2023553835A JP 2023553835 A JP2023553835 A JP 2023553835A JP 2023532465 A JP2023532465 A JP 2023532465A JP 2023532465 A JP2023532465 A JP 2023532465A JP 2023553835 A JP2023553835 A JP 2023553835A
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
pharmaceutically acceptable
acceptable salt
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023532465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553835A5 (cg-RX-API-DMAC7.html
Inventor
ジェイ ツイ,ジンロン
ルイ,ユージーン
ダブリュー ロジャーズ,エバン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BlossomHill Therapeutics Inc
Original Assignee
BlossomHill Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BlossomHill Therapeutics Inc filed Critical BlossomHill Therapeutics Inc
Publication of JP2023553835A publication Critical patent/JP2023553835A/ja
Publication of JP2023553835A5 publication Critical patent/JP2023553835A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP2023532465A 2020-12-17 2021-12-16 大環状化合物およびそれらの使用 Pending JP2023553835A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063126722P 2020-12-17 2020-12-17
US63/126,722 2020-12-17
US202163279850P 2021-11-16 2021-11-16
US63/279,850 2021-11-16
US202163284789P 2021-12-01 2021-12-01
US63/284,789 2021-12-01
US202163289014P 2021-12-13 2021-12-13
US63/289,014 2021-12-13
PCT/US2021/063721 WO2022133037A1 (en) 2020-12-17 2021-12-16 Macrocycles and their use

Publications (2)

Publication Number Publication Date
JP2023553835A true JP2023553835A (ja) 2023-12-26
JP2023553835A5 JP2023553835A5 (cg-RX-API-DMAC7.html) 2024-12-24

Family

ID=82058646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023532465A Pending JP2023553835A (ja) 2020-12-17 2021-12-16 大環状化合物およびそれらの使用

Country Status (12)

Country Link
US (1) US20240182487A1 (cg-RX-API-DMAC7.html)
EP (1) EP4262796A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023553835A (cg-RX-API-DMAC7.html)
KR (1) KR20230121773A (cg-RX-API-DMAC7.html)
AU (1) AU2021401741A1 (cg-RX-API-DMAC7.html)
CA (1) CA3202770A1 (cg-RX-API-DMAC7.html)
IL (1) IL303419A (cg-RX-API-DMAC7.html)
MX (1) MX2023007162A (cg-RX-API-DMAC7.html)
PY (1) PY21110949A (cg-RX-API-DMAC7.html)
TW (1) TWI923651B (cg-RX-API-DMAC7.html)
UY (1) UY39574A (cg-RX-API-DMAC7.html)
WO (1) WO2022133037A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250022117A (ko) * 2022-06-08 2025-02-14 블로썸힐 테라퓨틱스, 인크. 인다졸 거대고리 화합물 및 그의 용도
AU2023282906A1 (en) * 2022-06-08 2024-11-28 Blossomhill Therapeutics, Inc. Indazole containing macrocycles and their use
CN119013283A (zh) * 2022-07-27 2024-11-22 上海和誉生物医药科技有限公司 大环egfr抑制剂及其制备方法和药学上的应用
JP2026507655A (ja) * 2023-02-22 2026-03-04 ユーハン・コーポレイション Egfr阻害剤としての大環状アミノピリジン化合物
JP2026507653A (ja) * 2023-02-22 2026-03-04 ユーハン・コーポレイション Egfr阻害剤としての大環状アミノピリジン化合物
CN120981466A (zh) * 2023-02-22 2025-11-18 柳韩洋行 作为egfr抑制剂的大环氨基吡啶化合物
WO2024209363A1 (en) 2023-04-06 2024-10-10 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators
JP2026517554A (ja) * 2023-05-02 2026-06-02 ブロッサムヒル・セラピューティクス・インコーポレイテッド 疾患の処置のためのegfr阻害剤
JP2026521264A (ja) * 2023-06-23 2026-06-29 ブロッサムヒル・セラピューティクス・インコーポレイテッド 大環状インダゾール化合物の併用療法
TW202527935A (zh) * 2023-12-07 2025-07-16 美商榮山醫藥股份有限公司 吲唑巨環多晶型物
IL328856A (en) * 2023-12-08 2026-08-01 Blossomhill Therapeutics Inc Indazole-based macrocyclic compounds
WO2025199438A1 (en) * 2024-03-22 2025-09-25 Blossomhill Therapeutics, Inc. 7-azaindazole macrocycles and their use
WO2025245175A1 (en) * 2024-05-22 2025-11-27 Ajax Therapeutics, Inc. Macrocyclic heteroaromatic inhibitors of jak2
WO2026064346A1 (en) * 2024-09-18 2026-03-26 Blossomhill Therapeutics, Inc. Tetracyclic-macrocycles and their use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013538875A (ja) * 2010-10-05 2013-10-17 イーライ リリー アンド カンパニー 結晶((r)−(e)−2−(4−(2−(5−(1−(3,5−ジクロロピリジン−4−イル)エトキシ)−1h−インダゾール−3−イル)ビニル)−1h−ピラゾール−1−イル)エタノールおよびfgfr阻害剤としての使用
JP2018531218A (ja) * 2015-08-07 2018-10-25 ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド Fgfr及びvegfr阻害剤であるビニル化合物
CN111269245A (zh) * 2018-12-04 2020-06-12 杭州百新生物医药科技有限公司 一种环状氨基嘧啶衍生物及其抑制激酶的活性和用途
US20200197391A1 (en) * 2018-12-21 2020-06-25 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2863892C (en) * 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013538875A (ja) * 2010-10-05 2013-10-17 イーライ リリー アンド カンパニー 結晶((r)−(e)−2−(4−(2−(5−(1−(3,5−ジクロロピリジン−4−イル)エトキシ)−1h−インダゾール−3−イル)ビニル)−1h−ピラゾール−1−イル)エタノールおよびfgfr阻害剤としての使用
JP2018531218A (ja) * 2015-08-07 2018-10-25 ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド Fgfr及びvegfr阻害剤であるビニル化合物
CN111269245A (zh) * 2018-12-04 2020-06-12 杭州百新生物医药科技有限公司 一种环状氨基嘧啶衍生物及其抑制激酶的活性和用途
US20200197391A1 (en) * 2018-12-21 2020-06-25 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof

Also Published As

Publication number Publication date
PY21110949A (es) 2023-08-07
TW202241911A (zh) 2022-11-01
WO2022133037A1 (en) 2022-06-23
EP4262796A1 (en) 2023-10-25
IL303419A (en) 2023-08-01
MX2023007162A (es) 2023-06-29
TWI923651B (zh) 2026-05-01
EP4262796A4 (en) 2025-04-02
US20240182487A1 (en) 2024-06-06
KR20230121773A (ko) 2023-08-21
CA3202770A1 (en) 2022-06-23
AU2021401741A9 (en) 2024-09-19
AU2021401741A1 (en) 2023-06-29
UY39574A (es) 2022-07-29

Similar Documents

Publication Publication Date Title
TWI923651B (zh) 大環化合物及其用途
CN121487732A (zh) 用于治疗疾病的稠环kras抑制剂
JP6871903B2 (ja) プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
JP2021513534A (ja) 抗癌剤として有用なテトラヒドロキナゾリン誘導体
WO2018086591A1 (zh) 吡啶胺取代的杂三环化合物、其制法与医药上的用途
JP7713619B2 (ja) 大員環分子およびそれらの使用
TW202413377A (zh) 吲唑巨環化合物及其用途
CN120590414A (zh) 一类含氮杂环类化合物、制备方法和用途
IL324276A (en) Egfr inhibitors for treating disease
CN116635076A (zh) 大环化合物及其用途
HK40098660A (en) Macrocycles and their use
WO2025199438A1 (en) 7-azaindazole macrocycles and their use
WO2025235733A1 (en) Bis-bicycloheteroaryl macrocycles and their use
WO2026064346A1 (en) Tetracyclic-macrocycles and their use
WO2026101971A2 (en) Egfr inhibitors for treating disease
WO2025212729A1 (en) Macrocyclic compounds and their use
TW202547467A (zh) 雜芳基衍生化合物及其用途
KR20250056969A (ko) 마크로시클릭 이미다조[1,2-b]피리다진 유도체 및 이의 제조 방법과 용도
HK1231407B (en) Diaryl macrocycles as modulators of protein kinases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251021

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260616